Small Pharma Shares Business Update Ahead of Annual Financial Results
May 25, 2022 07:50 ET
|
Small Pharma Inc.
- Appointment of Alastair Riddell as COO- Two new Composition of Matter patents granted for pipeline projects- Progress continues across short-acting psychedelics portfolio LONDON, May 25, 2022 ...
Small Pharma to Participate in the PSYCH Symposium: London 2022
May 05, 2022 07:50 ET
|
Small Pharma Inc.
LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
March 10, 2022 08:18 ET
|
Small Pharma Inc.
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of...
Small Pharma to Participate in the 34th Annual Roth Conference
March 09, 2022 14:46 ET
|
Small Pharma Inc.
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuroscience company focused on psychedelic-assisted therapies for mental...
World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
February 22, 2022 08:30 ET
|
Small Pharma Inc.
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects on the...
Small Pharma Reports Fiscal Third Quarter 2021 Highlights
January 31, 2022 17:05 ET
|
Small Pharma Inc.
LONDON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted...
Small Pharma to Attend Upcoming Healthcare Conferences in January 2022
January 04, 2022 07:50 ET
|
Small Pharma Inc.
LONDON, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on...
Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021
December 01, 2021 08:49 ET
|
Small Pharma Inc.
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies,...
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
November 18, 2021 14:04 ET
|
Small Pharma Inc.
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies,...
Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
November 15, 2021 07:50 ET
|
Small Pharma Inc.
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies...